Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type  1 Spinal Muscular Atrophy

CONCLUSION: Long-term data supported risdiplam as a superior alternative to nusinersen in children with type 1 SMA. Video abstract available for this article. Video abstract (MP4 184542 KB).PMID:38705943 | DOI:10.1007/s12325-024-02845-6

Source: Adv Data - May 5, 2024 Category: Epidemiology Authors: Christos Kokaliaris Rachel Evans Neil Hawkins Anadi Mahajan David Alexander Scott C Simone Sutherland Julian Nam Gautam Sajeev Source Type: research